Table 1 A brief overview of clinical trials in the context of the MSC-based therapy for immune-mediated disorders registered in ClinicalTrails.gov (January 2021)
From: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders
Condition | Study phase | Cell source | Participant number | Location | NCT number |
|---|---|---|---|---|---|
GVHD | 2/3 | BM | 200 | China | NCT02241018 |
GVHD | 2 | BM | 15 | USA | NCT00284986 |
GVHD | 1/2 | UC | 30 | China | NCT01754454 |
GVHD | 2 | n/a | 30 | Belgium | NCT00504803 |
GVHD | 1/2 | BM | 10 | Pakistan | NCT02824653 |
GVHD | 1/2 | BM | 20 | Israel | NCT00749164 |
GVHD | 2 | BM | 40 | China | NCT01765634 |
GVHD | 1 | CF | 100 | China | NCT03123458 |
GVHD | 1/2 | UC | 27 | China | NCT04213248 |
GVHD | 3 | BM | 6 | Turkey | NCT03106662 |
GVHD | 1/2 | n/a | 25 | India | NCT00314483 |
GVHD | 1/2 | AT | 15 | Spain | NCT02687646 |
GVHD | 1/2 | UCB | 10 | S. Korea | NCT00823316 |
GVHD | 3 | n/a | 260 | USA | NCT00366145 |
GVHD | 1/2 | BM | 1 | USA | NCT02379442 |
GVHD | 13 | UCB | 30 | S. Korea | NCT01549665 |
GVHD | 2/3 | BM | 100 | China | NCT01526850 |
GVHD | 1/2 | AT | 19 | Spain | NCT01222039 |
GVHD | 2 | BM | 90 | Brazil | NCT02770430 |
GVHD | 2 | BM | 70 | Russian | NCT01941394 |
GVHD | 1 | BM | 10 | S. Korea | NCT01318330 |
GVHD | 1 | WJ | 10 | USA | NCT03158896 |
GVHD | 1/2 | UC | 40 | Malaysia | NCT03847844 |
SLE | 1/2 | OM | 10 | Belarus | NCT04184258 |
SLE | 1/2 | BM | 20 | China | NCT00698191 |
SLE | 1/2 | UC | 40 | China | NCT01741857 |
SLE | 2 | UC | 81 | USA | NCT02633163 |
SLE | 1 | UC | 6 | USA | NCT03171194 |
SLE | 1/2 | UC | 10 | France | NCT03562065 |
SLE | 2 | BM | 36 | Spain | NCT03673748 |
CD | 1/2 | BM | 20 | USA | NCT04519671 |
CD | 1/2 | AT | 15 | Spain | NCT01157650 |
CD | 1/2 | UC | 82 | China | NCT02445547 |
CD | 1/2 | BM | 21 | Netherlands | NCT01144962 |
CD | 2 | BM | 10 | USA | NCT00294112 |
CD | 1/2 | BM | 20 | Belgium | NCT01540292 |
CD | 3 | AT | 278 | Austria | NCT01541579 |
CD | 3 | n/a | 98 | USA | NCT00543374 |
CD | 1 | BM | 15 | USA | NCT04073472 |
CD | 1 | BM | 10 | Iran | NCT01874015 |
CD | 1/2 | UCB | 24 | S. Korea | NCT02000362 |
RA | 1/2 | AT | 53 | Spain | NCT01663116 |
RA | 1 | BM | 15 | Iran | NCT03333681 |
RA | 1/2 | AT | 54 | USA | NCT04170426 |
RA | 1 | BM | 20 | USA | NCT03186417 |
RA | 1 | UC | 16 | USA | NCT03828344 |
RA | 1/2 | UC | 200 | China | NCT01547091 |
RA | 1 | UC | 40 | China | NCT02643823 |
RA | 2/3 | BM | 60 | Iran | NCT01873625 |
RA | 1/2 | BM | 20 | Panama | NCT01985464 |
RA | 1/2 | AT | 15 | USA | NCT03691909 |
OA | 1/2 | UC | 15 | Indonesia | NCT04314661 |
OA | 1 | AT | 10 | Jordan | NCT02966951 |
OA | 1/2 | BM | 10 | Brazil | NCT01895413 |
OA | 1/2 | BM | 24 | India | NCT01985633 |
OA | 1/2 | AT | 18 | China | NCT01809769 |
OA | 1/2 | BM | 30 | Spain | NCT01586312 |
OA | 2 | BM | 32 | USA | NCT02958267 |
OA | 2 | n/a | 72 | Malaysia | NCT01448434 |
OA | 2 | BM | 40 | Iran | NCT01504464 |
OA | 2 | n/a | 60 | India | NCT01453738 |
OA | 1/2 | AT | 100 | Poland | NCT03869229 |
OA | 1/2 | BM | 30 | Spain | NCT02123368 |
OA | 3 | AT | 54 | Ecuador | NCT04351932 |
OA | 2 | UC | 60 | China | NCT03383081 |
OA | 1 | AT | 4 | Taiwan | NCT02544802 |
OA | 1 | UC | 20 | China | NCT02291926 |
OA | n/a | BM | 35 | USA | NCT03014037 |
OA | 3 | BM/UC/AT | 480 | USA | NCT03818737 |
OA | 1 | UCB | 12 | S. Korea | NCT04037345 |
OA | T | BM | 12 | Spain | NCT01183728 |
OA | 2/3 | BM | 25 | Egypt | NCT00891501 |
OA | 2 | AT | 28 | USA | NCT02674399 |
OA | n/a | BM | 20 | United Kingdom | NCT02696876 |
OA | n/a | BM | 100 | USA | NCT02582489 |
OA | n/a | AT | 100 | USA | NCT03379168 |
OA | 3 | UC | 103 | S. Korea | NCT01626677 |
OA | n/a | AT | 10 | USA | NCT01739504 |
OA | 1/2 | BM/P | 45 | Ukraine | NCT04453111 |
OA | 3 | UCB | 104 | S. Korea | NCT01041001 |
OA | 1 | UC | 125 | USA | NCT04043819 |
OA | 2 | BM | 13 | Jordan | NCT02118519 |
OA | 1/2 | WJ | 100 | Poland | NCT03866330 |
OA | n/a | BM/PB/AT | 35 | France | NCT01879046 |
OA | 2/3 | BM | 60 | Iran | NCT01873625 |
OA | 1/2 | AT | 18 | S. Korea | NCT01300598 |
OA | 1/2 | BM | 15 | Taiwan | NCT03589287 |
OA | 2 | UC | 60 | China | NCT03383081 |
MS | 1/2 | UC | 69 | Trinidad and Tobago | NCT02418325 |
MS | 1/2 | BM | 8 | Spain | NCT02495766 |
MS | 1/2 | UC | 60 | Jordan | NCT03326505 |
MS | 2 | n/a | 31 | Canada | NCT02239393 |
MS | 1 | BM | 7 | Sweden | NCT03778333 |
MS | 1/2 | n/a | 20 | Italy | NCT01854957 |
MS | 1/2 | BM | 22 | Iran | NCT01377870 |
MS | 1/2 | n/a | 15 | Sweden | NCT01730547 |
MS | 1/2 | BM | 1 | France | NCT02403947 |
MS | 1/2 | BM | 10 | United Kingdom | NCT00395200 |
MS | 1/2 | BM | 13 | Jordan | NCT01895439 |
MS | 1 | BM | 20 | USA | NCT01933802 |
MS | 1/2 | UC | 20 | Panama | NCT02034188 |
MS | 1/2 | BM | 9 | Spain | NCT02035514 |
MS | 1/2 | UC | 20 | China | NCT01364246 |
MS | 2 | n/a | 9 | Spain | NCT01228266 |
MS | 2 | BM | 50 | USA | NCT03355365 |
MS | 2 | BM | 20 | USA | NCT03799718 |
MS | 2 | BM | 48 | Israel | NCT02166021 |
ALI/ARDS | 1 | n/a | 70 | USA | NCT04629105 |
ALI/ARDS | 1/2 | UC | 75 | United Kingdom | NCT03042143 |
ALI/ARDS | 1/2 | WJ | 30 | Spain | NCT04390139 |
ALI/ARDS | 2 | BM | 40 | Germany | NCT04377334 |
ALI/ARDS | 1/2 | n/a | 24 | Australia | NCT04537351 |
ALI/ARDS | 1 | BM | 9 | Sweden | NCT04447833 |
ALI/ARDS | 1/2 | AT | 26 | Spain | NCT04289194 |
ALI/ARDS | 2 | BM | 10 | S. Korea | NCT02112500 |
ALI/ARDS | 1 | UC | 18 | Taiwan | NCT04347967 |
ALI/ARDS | 1 | WJ | 9 | Mexico | NCT04456361 |
ALI/ARDS | 1 | AT | 20 | China | NCT01902082 |
ALI/ARDS | 1 | UC | 10 | Mexico | NCT04416139 |
ALI/ARDS | 2/3 | UC/AT/BM | 60 | Iran | NCT04366063 |
ALI/ARDS | 1/2 | UC | 20 | China | NCT02444455 |
ALI/ARDS | 1 | WJ | 40 | Colombia | NCT04390152 |
ALI/ARDS | 2 | n/a | 30 | USA | NCT04466098 |
COVID-19 | 2 | UC | 16 | China | NCT04269525 |
COVID-19 | 1/2 | UC | 24 | USA | NCT04355728 |
COVID-19 | 1/2 | WJ | 30 | Spain | NCT04390139 |
COVID-19 | 1 | BM | 45 | USA | NCT04397796 |
COVID-19 | 1/2 | DP | 20 | China | NCT04336254 |
COVID-19 | n/a | UC | 48 | China | NCT04273646 |
COVID-19 | 1 | WJ | 9 | Mexico | NCT04456361 |
COVID-19 | 2 | UC | 10 | Mexico | NCT04416139 |
COVID-19 | 1 | WJ | 5 | Jordan | NCT04313322 |
COVID-19 | 1 | UC | 20 | China | NCT04252118 |
COVID-19 | 1 | AT | 20 | Mexico | NCT04611256 |
COVID-19 | 2 | n/a | 90 | Brazil | NCT04315987 |
COVID-19 | 1/2 | UC | 30 | China | NCT04339660 |
COVID-19 | 1 | UC | 70 | USA | NCT04565665 |
COVID-19 | 2 | UC | 100 | China | NCT04288102 |
COVID-19 | 1 | UC | 40 | USA | NCT04573270 |
COVID-19 | 2/3 | BM/UC/AT | 60 | Iran | NCT04366063 |
COVID-19 | 1 | n/a | 70 | USA | NCT04629105 |
COVID-19 | 1/2 | AT | 24 | Spain | NCT04366323 |
COVID-19 | 1/2 | OM | 40 | Belarus | NCT04382547 |
COVID-19 | 2 | UC | 102 | Spain | NCT04366271 |
COVID-19 | 1 | UC | 40 | Indonesia | NCT04457609 |
COVID-19 | 1/2 | WJ | 40 | Colombia | NCT04390152 |
COVID-19 | 2 | BM | 40 | Germany | NCT04377334 |
COVID-19 | 1/2 | UC/P | 30 | Ukraine | NCT04461925 |
COVID-19 | 1/2 | UC | 24 | USA | NCT04355728 |
COVID-19 | 3 | n/a | 300 | USA | NCT04371393 |
COVID-19 | 2 | n/a | 30 | USA | NCT04466098 |
COVID-19 | 1/2 | n/a | 24 | Australia | NCT04537351 |
COVID-19 | 2 | BM | 20 | Pakistan | NCT04444271 |
COVID-19 | 1/2 | UC | 75 | United Kingdom | NCT03042143 |
COVID-19 | 2 | AT | 100 | USA | NCT04362189 |
COVID-19 | 1/2 | UC | 30 | Turkey | NCT04392778 |